SE467909B - Anvaendning av komposition innehaallande fenylaettiksyraderivat foer framstaellning av ett laekemedel foer okulaer inflammation - Google Patents

Anvaendning av komposition innehaallande fenylaettiksyraderivat foer framstaellning av ett laekemedel foer okulaer inflammation

Info

Publication number: SE467909B
Authority: SE; Sweden
Prior art keywords: phenyl; eye; propionic acid; use according; prepared
Prior art date: 1983-08-10

Application number

SE8404019A

Other languages

English (en)

Swedish (sv)

Other versions

SE8404019D0 (sv

SE8404019L (sv

Inventor

M Fukami

Original Assignee

Sankyo Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-10

Filing date

1984-08-08

Publication date

1992-10-05

1984-08-08 Application filed by Sankyo Co filed Critical Sankyo Co

1984-08-08 Publication of SE8404019D0 publication Critical patent/SE8404019D0/xx

1985-02-11 Publication of SE8404019L publication Critical patent/SE8404019L/xx

1992-10-05 Publication of SE467909B publication Critical patent/SE467909B/sv

Links

206010061218 Inflammation Diseases 0.000 title claims description 6
230000004054 inflammatory process Effects 0.000 title claims description 6
239000000203 mixture Substances 0.000 title claims description 6
238000002360 preparation method Methods 0.000 title description 8
239000002253 acid Substances 0.000 title description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 32
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
-1 2-oxocyclohexylidenemethyl Chemical group 0.000 claims description 19
235000019260 propionic acid Nutrition 0.000 claims description 15
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 14
229940098465 tincture Drugs 0.000 claims description 12
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
239000011734 sodium Substances 0.000 claims description 7
229910052708 sodium Inorganic materials 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 6
239000003885 eye ointment Substances 0.000 claims description 6
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
239000003889 eye drop Substances 0.000 claims description 2
229940012356 eye drops Drugs 0.000 claims description 2
WTCKQPKTYSSOEZ-UHFFFAOYSA-N 2-[4-[(2-hydroxycyclopentylidene)methyl]phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C=C1C(O)CCC1 WTCKQPKTYSSOEZ-UHFFFAOYSA-N 0.000 claims 1
229960003424 phenylacetic acid Drugs 0.000 claims 1
239000003279 phenylacetic acid Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
229940126062 Compound A Drugs 0.000 description 7
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000000034 method Methods 0.000 description 6
230000000694 effects Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000007794 irritation Effects 0.000 description 4
229940094443 oxytocics prostaglandins Drugs 0.000 description 4
150000003180 prostaglandins Chemical class 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
210000002159 anterior chamber Anatomy 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000006196 drop Substances 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
230000002207 retinal effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000012085 test solution Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
101100067649 Caenorhabditis elegans gta-1 gene Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241001340526 Chrysoclista linneella Species 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
206010027646 Miosis Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
229960003872 benzethonium Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
201000001891 corneal deposit Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
210000003128 head Anatomy 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
231100001032 irritation of the eye Toxicity 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000003547 miosis Effects 0.000 description 1
231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
229940054534 ophthalmic solution Drugs 0.000 description 1
CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000029517 toxic amblyopia Diseases 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE8404019A 1983-08-10 1984-08-08 Anvaendning av komposition innehaallande fenylaettiksyraderivat foer framstaellning av ett laekemedel foer okulaer inflammation SE467909B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP58146147A JPS6038323A (ja)	1983-08-10	1983-08-10	眼科用消炎剤

Publications (3)

Publication Number	Publication Date
SE8404019D0 SE8404019D0 (sv)	1984-08-08
SE8404019L SE8404019L (sv)	1985-02-11
SE467909B true SE467909B (sv)	1992-10-05

Family

ID=15401196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8404019A SE467909B (sv)	1983-08-10	1984-08-08	Anvaendning av komposition innehaallande fenylaettiksyraderivat foer framstaellning av ett laekemedel foer okulaer inflammation

Country Status (13)

Country	Link
US (1)	US4599360A (da)
JP (1)	JPS6038323A (da)
BE (1)	BE900345A (da)
CA (1)	CA1225033A (da)
CH (1)	CH660965A5 (da)
DE (1)	DE3429570C2 (da)
DK (1)	DK161668C (da)
FR (1)	FR2552993B1 (da)
GB (1)	GB2144993B (da)
IT (1)	IT1196220B (da)
NL (1)	NL192561C (da)
SE (1)	SE467909B (da)
ZA (1)	ZA846166B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968718A (en) *	1988-01-25	1990-11-06	University Of Iowa Research Foundation	Topically effective, nonsteroidal drug for use in external and internal eye inflammations
US5179124A (en) *	1988-01-25	1993-01-12	University Of Iowa Research Foundation	Anti-inflammatory for use in external and internal eye inflammations
US5360611A (en) *	1988-10-03	1994-11-01	Alcon Laboratories, Inc.	Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5624893A (en) *	1993-10-14	1997-04-29	Alcon Laboratories, Inc.	Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US6162393A (en)	1998-08-06	2000-12-19	Ndt, Inc.	Contact lens and ophthalmic solutions
US7678836B2 (en) *	1999-11-04	2010-03-16	Fxs Ventures, Llc	Method for rendering a contact lens wettable
US8557868B2 (en)	2000-11-04	2013-10-15	Fxs Ventures, Llc	Ophthalmic and contact lens solutions using low molecular weight amines
AU2002239545B2 (en) *	2000-11-08	2006-10-05	Fxs Ventures, Llc	Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
US20060148665A1 (en) *	2000-11-08	2006-07-06	Bioconcept Laboratories	Ophthalmic and contact lens solutions containing forms of vitamin b
US9492582B2 (en) *	2000-11-08	2016-11-15	Fxs Ventures, Llc	Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20070098813A1 (en) *	2000-11-08	2007-05-03	Fxs Ventures, Llc	Ophthalmic and contact lens solutions with a peroxide source and a preservative
US20070104744A1 (en) *	2000-11-08	2007-05-10	Fxs Ventures, Llc	Ophthalmic and contact lens solutions containing forms of vitamin b
US9308264B2 (en)	2000-11-08	2016-04-12	Fxs Ventures, Llc	Ophthalmic contact lens solutions containing forms of vitamin B
US20060127496A1 (en) *	2000-11-08	2006-06-15	Bioconcept Laboratories	L-histidine in ophthalmic solutions
US20070110782A1 (en) *	2000-11-08	2007-05-17	Fxs Ventures, Llc	L-histidine in ophthalmic solutions
DE60140007D1 (de) *	2000-11-08	2009-11-05	Fxs Ventures Llc	Verbesserte ophthalmische und kontaktlinsenlösungen mit einfachen sacchariden als konservierungsverbesserer
CA2450073C (en)	2001-07-25	2017-08-29	Biomarin Pharmaceutical Inc.	Compositions and methods for modulating blood-brain barrier transport
WO2004091438A2 (en) *	2003-04-15	2004-10-28	Fxs Ventures, Llc	Improved ophthalmic and contact lens solutions containing peptides as representative enhancers
EP2671508B1 (en)	2005-04-28	2020-09-16	Proteus Digital Health, Inc.	Pharma-informatics system
JP2010503710A (ja)	2006-09-18	2010-02-04	ラプトールファーマシューティカルインコーポレイテッド	受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
ES2919563T3 (es)	2009-02-20	2022-07-27	Enhanx Biopharm Inc	Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko)	2009-05-06	2018-10-19	라보라토리 스킨 케어, 인크.	활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en)	2010-09-29	2012-03-29	Andrea Bourdelais	Ladder-Frame Polyether Conjugates
CN111825547B (zh) *	2019-04-23	2022-04-19	南京海融医药科技股份有限公司	一种芳基丙酸类化合物的盐及其制药用途
KR102200892B1 (ko) *	2019-05-13	2021-01-12	대원제약주식회사	펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
KR102462607B1 (ko) *	2020-11-11	2022-11-03	대원제약주식회사	펠루비프로펜 신규 염을 주성분으로 하는 안정성이 증가된 약학적 조성물
KR102552315B1 (ko) *	2020-11-11	2023-07-06	대원제약주식회사	펠루비프로펜 신규 염을 주성분으로 하며 위장장애 부작용이 저감된 약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB971700A (en) *	1961-02-02	1964-09-30	Boots Pure Drug Co Ltd	Anti-Inflammatory Agents
US3865949A (en) *	1973-08-02	1975-02-11	Upjohn Co	Process of treatment
US4161538A (en) *	1977-04-05	1979-07-17	Sankyo Company Limited	Substituted phenylacetic acid derivatives and process for the preparation thereof
JPS5432460A (en) *	1977-08-16	1979-03-09	Sankyo Co Ltd	Cycloalkylidenemethylphenylacetic acid derivative and their preparation
DD141422A5 (de) *	1978-01-27	1980-04-30	Schering Ag	Verfahren zur herstellung von phenylessigsaeure-derivaten
CH645539A5 (de) *	1980-06-09	1984-10-15	Sankyo Co	Antiinflammatorische mittel fuer die aeusserliche anwendung.
JPS5757019A (en) *	1980-09-24	1982-04-06	Fujitsu Ltd	Surface acoustic wave filter
JPS57106617A (en) *	1980-12-23	1982-07-02	Sankyo Co Ltd	Analgesic and anti-inflammatory agent
JPS6033718B2 (ja) *	1981-06-27	1985-08-05	石川島播磨重工業株式会社	船舶の操舵装置
JPS58105939A (ja) *	1981-12-18	1983-06-24	Sankyo Co Ltd	置換フエニル酢酸誘導体及びその製法
JPS59196839A (ja) *	1983-04-21	1984-11-08	Sankyo Co Ltd	フエニル酢酸誘導体

1983
- 1983-08-10 JP JP58146147A patent/JPS6038323A/ja active Pending
1984
- 1984-08-08 SE SE8404019A patent/SE467909B/sv not_active IP Right Cessation
- 1984-08-09 US US06/639,376 patent/US4599360A/en not_active Expired - Lifetime
- 1984-08-09 NL NL8402463A patent/NL192561C/nl not_active IP Right Cessation
- 1984-08-09 ZA ZA846166A patent/ZA846166B/xx unknown
- 1984-08-09 CH CH3832/84A patent/CH660965A5/de not_active IP Right Cessation
- 1984-08-09 IT IT22291/84A patent/IT1196220B/it active
- 1984-08-10 BE BE0/213484A patent/BE900345A/fr not_active IP Right Cessation
- 1984-08-10 CA CA000460814A patent/CA1225033A/en not_active Expired
- 1984-08-10 DE DE3429570A patent/DE3429570C2/de not_active Expired - Fee Related
- 1984-08-10 FR FR848412713A patent/FR2552993B1/fr not_active Expired
- 1984-08-10 GB GB08420364A patent/GB2144993B/en not_active Expired
- 1984-08-10 DK DK387784A patent/DK161668C/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
CH660965A5 (de)	1987-06-30
CA1225033A (en)	1987-08-04
FR2552993A1 (fr)	1985-04-12
DK387784A (da)	1985-02-11
JPS6038323A (ja)	1985-02-27
SE8404019D0 (sv)	1984-08-08
GB2144993B (en)	1987-03-11
NL192561C (nl)	1997-10-03
DE3429570A1 (de)	1985-02-28
DK161668B (da)	1991-08-05
FR2552993B1 (fr)	1989-03-10
DE3429570C2 (de)	1995-02-02
IT1196220B (it)	1988-11-16
NL8402463A (nl)	1985-03-01
SE8404019L (sv)	1985-02-11
NL192561B (nl)	1997-06-02
DK161668C (da)	1992-02-24
GB8420364D0 (en)	1984-09-12
US4599360A (en)	1986-07-08
GB2144993A (en)	1985-03-20
ZA846166B (en)	1985-04-24
DK387784D0 (da)	1984-08-10
BE900345A (fr)	1984-12-03
IT8422291A0 (it)	1984-08-09

Legal Events

Date

Code

Title

Description

1995-01-31

NAL

Patent in force

Ref document number: 8404019-5

Format of ref document f/p: F

2002-04-02

NUG

Patent has lapsed